Following the Consensus Analyst Rating on These Shares: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Wall Street analysts have the ability to provide stock ratings for companies that they track. Based on analysts used by Zacks Research, the present average broker rating on shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is currently 1.58. This mean rating includes analysts who have offered Sell, Buy and Hold ratings on the equity. This rating lands on a numerical recommendation scale from 1 to 5. A score of 1 would represent a Buy recommendation, and a score of 5 would indicate a Sell recommendation. Out of all the analysts providing ratings, 15 have rated the stock a Strong Buy or Buy, based on data provided by Zacks Research. 

Investors may be looking at all the different factors that come into play when searching for those next stocks to add to the portfolio. Maybe there are some names that have been on the radar, but the timing hasn’t been right to add them into the mix. As we get closer to the end of the year, investors may be looking back at individual stock performance over the past year. They may discover some great opportunities that weren’t available during the last review. Investors may also be keeping an eye on which sectors were the big winners during the latest earnings season. Branching out into new areas may help give the investor some alternative ideas for the next few quarters.

Zooming in on recent stock price action for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), we note that shares are trading near the 184.01 level. Investors will often follow stock price levels in relation to the 52-week high and low levels. The 52-week high is presently 194.7, and the 52-week low is sitting at 145.72. When a stock price is getting close to either the 52-week high or 52-week low, investors may track activity to watch for a move past the established mark. Over the last 12 weeks, shares have seen a change of 15.18%. Heading further back to the start of the year, we note that shares have seen a change of 11.04%. Focusing in closer to the last 4 weeks, shares have seen a change of -1.43%. Over the past five trading days, the stock has changed -1.61%.

Sell-side Wall Street analysts will commonly offer stock price target estimates. Many investors pay close attention to where the analysts project the stock moving in the future. After a recent scan, we can see that analysts polled by Zacks Research have set a consensus price target of $205.75 on shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Price target estimates can be calculated using various methods, and they may be quite different depending on the individual analyst. A fully researched analyst report will generally provide detailed reasoning for a specific target price prediction. Some investors may track analyst targets very closely and use the information to complement their own stock research.

Taking a quick look at the current quarter EPS consensus estimate for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), we can see that the most recent level is sitting at 0.99. This EPS projection uses 11 Sell-Side analysts polled by Zacks Research. For the previous reported quarter, the company posted a quarterly EPS of 1.3. Covering analysts have the tough job of following companies and offering future estimates. These estimates are often closely followed on the Street, and earnings beats or misses revolve around these projections. Sometimes these predictions are extremely close to the actual reported number, and other times they may be way off. When a company posts actual earnings numbers, the surprise factor can lead to sudden stock price fluctuations. If a company meets and beats estimates and posts a positive earnings surprise, the stock may see a near-term bump. On the other end, a negative surprise may send the stock in the opposite direction. Many investors will choose to trade with caution around earnings releases and wait to make a move until after the major activity has subsided.

It can be very difficult to keep emotions on the sidelines when making important investing decisions. Even if all the number crunching is done unemotionally, there may be a tendency for those feelings of excitement or dread to creep in. Once the trade is made, it can be super difficult to make sane decisions when markets go haywire. Investors may have made some trades that didn’t pan out as planned, and they may have the itch to sell quickly in order to stop further losses. Selling a stock just because it is going down or buying a stock just because it is going up, might lead to portfolio struggles in the future. Obtaining a grasp on the bigger picture may help investors see through the cloudiness and make clearer decisions when the time comes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.